Pathophysiology and Treatment of Fibromyalgia Syndrome

Authors: Stratz, Thomas; Schneider, Marion; Joos, Thomas O.; Hsu, Hsin-Yun; Muller, Wolfgang

Source: Current Rheumatology Reviews, Volume 3, Number 2, May 2007 , pp. 167-170(4)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $62.88 plus tax (Refund Policy)

Abstract:

Fibromyalgia syndrome is not a diagnosis in itself, but merely represents a set of classification criteria. It is possible to distinguish between different subgroups. Such a distinction can be made on the basis of psychopathological, clinical and laboratory tests. One subgroup reveals elevated level of different cytokines. The treatment of primary fibromyalgia can be optimized by taking these subgroups into consideration since one group responds better to 5-HT3 receptor antagonists, whereas another benefits more from antidepressants and a third group from psychotherapy. In socalled secondary fibromyalgia, 5-HT3 receptor antagonists may be used in the attempt to manage pain that might still persist after treatment of the primary disease.

Keywords: Fibromyalgia; subgroups; antidepressants; treatment; tropisetron; 5-HT3-receptor antagonists; psychotherapy

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157339707780619386

Affiliations: 1: Park-Klinik Bad Sackingen,Weihermatten 1, D-79713 Bad Sackingen, Germany.

Publication date: 2007-05-01

More about this publication?

Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field.

The journal is essential reading for all researchers and clinicians in rheumatology.